86 results about "Liver failure" patented technology

Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred embodiment subject matter of the invention is an anti-ADM antibody or an anti-adrenomedullin antibody fragment or anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of kidney dysfunction or kidney failure or liver dysfunction or liver failure.

The invention discloses a long-term prognosis prediction system and method for patients with liver diseases, and the method comprises the following steps: S1, collecting clinical data, including anthropometric data, vital signs, laboratory data and albumin binding capacity obtained by specific detection, of patients with acute decompensation of liver cirrhosis and chronic plus acute liver failure; s2, a competitive risk model for predicting death of patients suffering from acute decompensation of liver cirrhosis and chronic and acute hepatic failure after admission for one year is constructed, the prediction model is constructed by adopting the competitive risk model, and a convenient prediction tool is made by adopting a dynamic column diagram visual prediction model; and S3, evaluating the prediction performance of the model through the working curve of the subject. According to the present invention, the index relationship between the albumin binding capacity and the long-term prognosis of the decompensated liver cirrhosis patient and the chronic plus acute liver failure patient is established so as to provide the important clinical significance, such that the clinical management can be further optimized, and the drug treatment can be guided.

The invention relates to the technical field of hepatic failure treatment, and particularly discloses application of tsRNA-20 or a simulant thereof in preparation of drugs for treating chronic plus acute hepatic failure and / or promoting liver cell proliferation. Through tsRNA sequencing and qRT-PCR verification, down-regulated expression of the tsRNA-20 in a plasma sample and liver tissue in chronic and acute hepatic failure is determined, and cell experiments find that the tsRNA-20 regulates an ACPH / GRHL1 axis to promote liver cell proliferation. Specifically, it is found that tsRNA-20 is combined with an amidyl peptide hydrolase (ACPH), so that a Ras-ERK pathway is activated, nuclear translocation of a granulocyte-like transcription factor 1 (GRHL1) is promoted, and finally liver cell proliferation is enhanced. Therefore, when the tsRNA-20, the precursor tRNA-GIy-CCC thereof and the regulated objects ACPH and GRHL1 thereof are applied to treatment of the chronic and acute liver failure, the tsRNA-20, the precursor tRNA-GIy-CCC thereof and the regulated objects ACPH and GRHL1 thereof can be used as targets to be regulated to promote liver cell proliferation, so that liver regeneration is promoted, the treatment effect of the chronic and acute liver failure is improved, the lifetime of patients with liver diseases is prolonged, and the tsRNA-20, the precursor tRNA-GIy-CCC and the regulated objects ACPH and GRHL1 possibly become new targets for precise treatment. The clinical application value is relatively high.

The invention belongs to the technical field of biomedical engineering, and discloses a multiple biomarker detection system for diagnosis and classification of hepatic failure acute kidney injury, comprising a biomarker library construction module for obtaining historical hepatic failure acute kidney injury data to construct a biomarker library; the historical hepatic failure acute kidney injury data comprises biomarker data, pathological image data and patient clinical data; the data processing module is used for preprocessing the acquired biomarker data, pathological image data and patient clinical data to obtain a biomarker feature data set, a pathological image feature data set and a clinical feature data set; the acute kidney injury diagnosis module is used for fusing the biomarker feature data set, the pathological image feature data set and the clinical feature data set to obtain a comprehensive feature data set; inputting the comprehensive feature data set into a trained acute kidney injury diagnosis model, and predicting to obtain acute kidney injury type data; and the diagnosis accuracy is improved.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

The present invention relates to compounds of formula 1: # imgabs0 # and their use as STING antagonists, for example, the composition is used for treating diseases selected from the group consisting of systemic lupus erythematosus (SLE), (single and double gene) interferon diseases (including STING-related vascular disease (SAVI), Aicardi-Goutires syndrome (AGS), COPA syndrome and familial chilblain-like lupus, DNASE2 or ATAD3A gene mutated type I interferon disease, age-related macular degeneration (AMD), retinopathy, glaucoma, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, lupus erythematosus, and lupus erythematosus. Amyotrophic lateral sclerosis (ALS), diabetes, obesity, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), Bloom syndrome, sicca syndrome, Parkinson's disease, heart failure and cancer, systemic sclerosis (SSc), dermatomyositis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), chronic plus acute liver failure (ACLF), interstitial lung disease (ILD), idiopathic pulmonary fibrosis (IPF), and the like. , aging / muscle disease, sepsis, heart failure, rheumatoid arthritis, and osteoarthritis.

This invention discloses a polyethylene glycol-modified magnesium boride nanosheet and its application in treating acute liver failure and hepatic encephalopathy caused by acetaminophen. The nanosheet uses magnesium boride nanosheets as a core, with polyethylene glycol modified on the surface to improve biocompatibility. The nanosheet of this invention exhibits good antioxidant properties and can be used to prepare nanomedicines for treating acute liver failure and / or hepatic encephalopathy caused by acetaminophen. It generates reducing hydrogen gas through a hydrolysis reaction, effectively scavenging reactive oxygen species at the site of liver failure, thereby inhibiting inflammatory responses and effectively alleviating symptoms caused by acute liver failure.

Methods and compositions of matter useful for preventing or reversing liver failure. Autologous hepatic progenitors are generated from pluripotent stem cells and administered in a manner to augment and / or replace endogenous regenerative processes. Generation of "adjuvant cells" to enhance engraftment and function of hepatic progenitors. Compositions and methods of reversing liver fibrosis whether caused by viral or chemical toxicity.

The invention relates to application of serum mucoid or Tax1 binding protein 1 in preparation of a medicine for treating medicine-induced liver injury or organ ischemia-reperfusion injury. Experiments prove that by using an adeno-associated virus (AAV) carrying an Orm2 gene, ORM2 recombinant protein or knocking down a TAX1BP1 gene, liver injury and liver failure, ischemia reperfusion injury of the liver, ischemia reperfusion injury of the kidney and ischemia reperfusion induction of intestines induced by APAP treatment can be effectively relieved, and the application has the advantages that the liver injury and liver failure, the ischemia reperfusion injury of the kidney and the ischemia reperfusion induction of the intestine can be effectively relieved; and a new target spot and a new treatment method are provided for treating the ferroptosis-related organ injury.

The present invention relates to the field of liver disease, and more particularly to a method for determining the presence of chronic plus acute liver failure or for determining the risk of developing ACLF in a patient suffering from cirrhosis or a delayed early stage of ACLF. The invention also relates to a method for distinguishing patients suffering from decompensated liver cirrhosis, acute decompensated liver cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, a method for determining the degree of systemic inflammation and a method for determining the presence of a bacterial infection with sepsis.

A lipid-containing composition, by weight, includes phospholipids, and one or more of vegetable oil, medium-chain triglycerides, antioxidants, and sodium oleate. It has been verified that the various compositions provided by this invention competitively capture protein-bound toxoids in the blood, thereby achieving the purpose of clearing protein-bound toxoids from the blood, especially for patients with liver failure, and also alleviating oxidative stress in patients during dialysis treatment.

The invention discloses application of ANGPTL3 in prognosis of hepatitis B related chronic-acute liver failure, and relates to the technical field of disease prognosis and biological medicine. The invention discloses application of ANGPTL3 as a biomarker in preparation of a product for diagnosis and / or disease course diagnosis and / or prognosis evaluation of hepatitis B related chronic plus acute liver failure. The invention has the following beneficial effects: ANGPTL3 can be used as a biomarker for prognosis of hepatitis B-related chronic-acute liver failure, blood sample levels of patients in different groups of HBV-ACLF and dynamic ANGPTL3 levels are absolutely quantified by ELISA technology, and hepatitis B-related chronic-acute liver failure phenomena and disease courses can be timely found and detected with other related indexes; therefore, the ANGPTL3 is utilized to provide scientific guidance for management and decision-making of hepatitis B related chronic plus acute liver failure.

Use of targeted inhibition of p300 / CBP in treating liver injury diseases, and a method for preventing and / or treating liver injury diseases by targeted inhibition of p300 / CBP in a subject in need thereof, the liver injury diseases comprising acute liver injury, chronic liver injury and / or liver failure, and acute-on-chronic liver failure. A p300 / CBP inhibitor has broad market application prospects in the treatment of acute and chronic liver injury and / or liver failure and acute-on-chronic liver failure.

The application belongs to the technical field of biological detection, and particularly relates to the use of apolipoprotein A-I in the preparation of a diagnostic reagent or system for predicting the risk of severe acute hepatitis E. The application first discloses and verifies the significant correlation between the serum apolipoprotein A-I (apoA-I) level and the adverse clinical outcomes (including severe jaundice, liver failure and death) of patients with acute hepatitis E, and establishes the risk interpretation threshold (0.675 g / L and 0.435 g / L) with clinical practical value. The application can objectively and early identify high-risk patients, and provides a powerful auxiliary tool for clinical stratified management and resource optimization.

The invention relates to application of a biomarker diamine oxidase (DAO) in prediction, diagnosis and treatment of chronic plus acute liver failure (ACLF). The invention also relates to correlation analysis of DAO and ACLF diagnostic markers such as TBIL, INR and the like. On the basis of existing TBIL and INR index models, the DAO index is added, early warning can be conducted on ACLF, complex instruments, equipment and schemes are not needed for DAO concentration detection, the detection period is short, and therefore a new marker is provided for clinical diagnosis and treatment of ACLF, and important clinical significance is achieved.

The invention relates to the technical field of liver care, in particular to a liver postoperative care process state evaluation method and system. According to the method, the multiple groups of indexes and the image group feature data are combined, so that the liver nursing, especially the hepatic failure degree after the hepatic resection can be effectively evaluated, the score data reflecting the current hepatic failure development state after the hepatic resection can be obtained, and the wind direction degree can be more intuitively determined through the score data; therefore, the overall automatic prediction of the hepatic failure degree after the hepatic resection is realized.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

The invention discloses a preparation method and application of a hepatic parenchymal cell targeting gene delivery system, and relates to construction and preparation of a hepatic parenchymal cell targeting lipid material GalNAc-PEG2000-DSPE modified MKK4-siRNA (siMKK4) loaded lipid nanoparticle gene delivery system GalNAc-LNP-siMKK4, and the hepatic parenchymal cell targeting gene delivery system can be used for active targeting gene therapy of hepatic failure. The parenchymal hepatic cell targeted gene delivery system selects siMKK4 as a liver regeneration promoting gene therapy drug, has the advantages of clear target spot and capability of accurately silencing a target gene, and can protect siMKK4 from being degraded by extracellular nuclease as a gene delivery carrier, so that the targeted gene delivery system has a good application prospect. N-acetylgalactosamine (GalNAc) is selected as a target head, so that therapeutic genes can be precisely targeted and delivered to parenchymal hepatic cells, the risk of tumorigenesis of other parts of an organism can be reduced while liver regeneration is promoted, and a new thought and a new method are provided for liver regeneration treatment of hepatic failure patients.

The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit Yellow Fever Virus (YFV) viral genome expression. Also disclosed are pharmaceutical compositions that include YFV RNAi agents and methods of use thereof. The YFV RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the YFV RNAi agents in vivo provides for inhibition of YFV viral genome expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms caused by YFV infection, such as liver failure.

Compositions of matter and therapeutic methods for preventing, reducing, or reversing liver pathologies. Autologous pluripotent stem cells for generating monocytes or macrophages that are capable of suppressing liver failure. Methods of administering monocytes that are engineered or induced to facilitate hepatic regeneration. Hepatogenic cells such as monocytes are generated from induced pluripotent stem cells. Hepatogenic cells can be generated by overexpression of one or a plurality of factors associated with an M2 phenotype in pluripotent stem cell-derived monocytes such as signal transducer and activator of transcription 6 (STAT6) and transforming growth factor-beta. Hepatogenic monocytes can be generated in an environment that simulates liver injury.

The present invention relates to compounds for use in the treatment of liver failure.

The invention relates to a specific liver microtissue, the largest dimension of which is between 500 and 700 μm, which expresses monooxygenase CYP3A4 with an activity of at least 75,000 RLU per million cells and produces at least 18 μg of urea per million cells in 24 hours. The invention also relates to a method for preparing a liver microtissue of this kind and to the uses thereof in the treatment or prevention of liver failure.

Overt hepatic encephalopathy is a serious complication of cirrhosis and affects lipid and lipoprotein metabolism. The present invention relates to a biomarker for the prognosis of hepatic encephalopathy. The biomarker includes one or more of high-density lipoprotein cholesterol, model for end-stage liver disease score, age, gender, upper gastrointestinal bleeding, spontaneous bacterial peritonitis, overt hepatic encephalopathy grade, ascites, aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum albumin, total cholesterol, low-density lipoprotein cholesterol, serum creatinine, neutrophil-lymphocyte ratio, prothrombin time, and prothrombin activity level. Compared with patients with alcoholic hepatitis, liver disease, liver failure, etc. proposed in the prior art, due to the specificity of the target population, the biomarker proposed in this application can significantly improve the accuracy of the assessment of the prognosis of overt hepatic encephalopathy.

Methods are disclosed for treating end-stage liver failure in a subject that include administering to the subject a therapeutically effective amount of a recombinant mRNA encoding HNF4α isoform 2. The methods can include administering a lipid nanoparticle including the recombinant mRNA to the subject. Also disclosed are recombinant mRNA encoding an HNF4α isoform 1 or HNF4α isoform 2, and lipid nanoparticles include the recombinant mRNA. Methods are also for treating liver disease or end-stage liver failure in a subject that include administering to the subject a therapeutically effective amount of a recombinant mRNA encoding HNF4α isoform 1.

The present application relates to a kind of protein combination, kit and system for predicting secondary infection of hepatitis B related liver failure patient, including the use of protein combination in the preparation for predicting secondary infection of hepatitis B related liver failure patient, the combination includes lysozyme LYZ, calmodulin 1 CALM1, heparin cofactor II SERPIND1 and cutin DPT.It is directly reflected that the combination is biomarker "inflammation-coagulation imbalance" this core mechanism of liver disease secondary infection, with high specificity, and the combination is not interfered by liver disease background, more can truly reflect the potential reaction state of body to infection under liver disease background, to overcome the problem of "failure" and "false negative" of traditional index ";The combination can significantly change concentration when patient is admitted to hospital early, without clinical infection signs, to provide key time window for early preventive treatment.

The invention provides an application of SETDB1 as a drug target for preventing and / or treating acute liver injury and hepatic failure. The acute liver injury and hepatic failure are relieved by knocking out an SETDB1 gene or inhibiting SETDB1 enzyme activity. Experiments prove that the SETDB1 gene is specifically knocked out of the liver or a small-molecule inhibitor SETDB1-TTD-IN-1 is used, acute liver injury and hepatic failure induced by acetaminophen can be remarkably relieved, and the acute liver injury and hepatic failure are shown as reduction of hepatic cell necrosis and remarkable improvement of liver function indexes. The discovery provides new targets and candidate compounds for developing specific drugs for treating acute liver injury and hepatic failure, and has important clinical transformation value.

To provide a therapy guidance and / or therapy monitoring for treatment with an angiotensin-receptor-agonist and / or a precursor thereof.SOLUTION: Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, wherein the disease is selected from the group consisting of heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and wherein the subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.SELECTED DRAWING: None

The present invention provides an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce organ dysfunction or organ failure. In a preferred embodiment, the invention provides an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce renal dysfunction or renal failure or hepatic dysfunction or hepatic failure.

This invention discloses the application of β-hydroxybutyric acid (BHB) in the preparation of products that promote hepatocyte proliferation and liver regeneration. This invention discovers that β-hydroxybutyric acid can promote liver regeneration and recovery by promoting the proliferation of hepatocytes in the residual liver after partial hepatectomy. Therefore, β-hydroxybutyric acid can be used to prepare products that promote liver regeneration. This invention not only discloses the application of β-hydroxybutyric acid in promoting liver regeneration, providing a drug source for the development of products that promote liver regeneration, but also provides a theoretical basis for subsequent clinical intervention strategies to promote liver regeneration. This helps to improve liver regeneration capacity and avoid poor prognosis and liver failure caused by insufficient liver regeneration capacity after partial hepatectomy or living donor liver transplantation.

The lipid-containing composition comprises phospholipid, and one or more of vegetable oil, medium-chain triglyceride, an antioxidant and sodium oleate according to a weight ratio. Through verification, various compositions provided by the invention have the effect of competitively capturing the protein-binding toxoid in the blood, so that the purpose of removing the protein-binding toxoid in the blood is achieved, and particularly, the effect of removing the protein-binding toxoid in the blood of a liver failure patient is more obvious; the oxidative stress state of a patient in the dialysis treatment process is also relieved.